Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BridgeBio Pharma Inc (BBIO) vs Verizon Communications Inc (VZ) Price & Performance

BridgeBio Pharma IncTrade
Verizon Communications IncTrade

Price performance (Past 24H)

Key statistics

BridgeBio Pharma Inc vs Verizon Communications Inc — how do they compare? BridgeBio Pharma Inc trades at $83.61 (market cap $16.36B), while Verizon Communications Inc trades at $47 (market cap $196.40B). The key difference: Verizon Communications Inc is far larger — about 12× BridgeBio Pharma Inc's market cap, and Verizon Communications Inc pays a 5.99% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.

BBIOVZ
Market Cap
$16.36B$196.40B
Sector
HealthMedia
52-Week High
$90.17$51.38
52-Week Low
$47.29$38.40
Enterprise Value
$18.14B$383.10B
Volume
22,584,735
Dividend Yield
5.99%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BridgeBio Pharma Inc

BridgeBio Pharma (BBIO) trades at $84.67, up 0.22% today, with a bullish technical signal and strong analyst consensus. Despite missing Q2 2026 EPS estimates with a loss of $0.78 per share, revenue beat expectations as Attruby sales surged 311% year-over-year. The company maintains a high gross margin of 94.44% but reports negative net income and cash flow from operations, reflecting its growth investment phase.

The outlook is optimistic due to multiple late-stage pipeline catalysts, including three potential product launches by mid-2027 and an FDA decision on encaleret by May 2027. Risks include sustained cash burn, high debt of $1.72 billion, and clinical trial execution. The consensus price target of $104.56 implies significant upside if commercial execution succeeds.

Verizon Communications Inc

Verizon (VZ) trades at $47.03, down 0.06% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $49.69. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $1.30 surpassing the $1.27 estimate. The company maintains strong cash flow from operations at $37.14 billion in 2025 and a healthy dividend yield, supported by a $0.71 per share payout scheduled for August 2026.

VZ presents a value opportunity with a low P/E of 12.31 and stable revenue around $138 billion, though competitive pressures from new entrants like SpaceX's Starlink and high debt levels pose risks. Analyst sentiment is mixed with 36.7% buy ratings, but fundamentals suggest resilience for income-focused investors seeking telecom exposure.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Read more on BBIO

About Verizon Communications Inc

Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.

Read more on VZ